FILTER

Refine your search with the following facets to narrow down your results.

8,308 Current news from the industry healthcare

Exercise training in ordinary people affects the activity of 500 genes

06-May-2005 - A new study from Karolinska Institutet in Stockholm shows that hundreds of genes in the thigh muscle are activated in regular cycle training. The study also reveals that great differences in training response may be due to the ability in some people to activate their genes much more forcefully. ...

cardiovascular diseases diseases genes +1

Serono and Genmab sign worldwide agreement to develop and commercialize Humax-TAC

04-May-2005 - Serono and Genmab A/S announced that they have signed an agreement under which Genmab grants Serono exclusive worldwide rights to develop and commercialize Genmab's HuMax-TAC. The product is a fully human monoclonal antibody targeting the TAC antigen - also known as CD25, or the interleukin-2 ...

antigens clinical trials Genmab +3

YM BioSciences completes acquisition of DELEX

04-May-2005 - YM BioSciences Inc. announced it has completed the purchase of DELEX Therapeutics Inc., a private clinical stage biotechnology company developing inhalation delivered fentanyl products to treat cancer pain. DELEX's lead product is AeroLEF(TM), a proprietary technology for the treatment of acute ...

biotechnology cancer pain pain

Generex Biotechnology Begins Testing New Vaccine for Breast Cancer Patients

02-May-2005 - Generex Biotechnology Corporation announced that the first patients had received a novel therapeutic vaccine developed by its wholly owned subsidiary, Antigen Express as part of the Company's Phase I Trial. The Trial will include between 16 and 24 patients. The compound, AE37, is designed to ...

breast cancer clinical trials colon cancer +3

Pharmexa and GSK will not start negotiations on breast cancer vaccine

02-May-2005 - GlaxoSmithKline (GSK) has now informed Pharmexa of their decision not to exercise a previously granted right to negotiate a license agreement on Pharmexa's HER-2 Protein AutoVac(TM) vaccine. The vaccine recently started phase II trials in breast cancer. As described in the prospectus dated April ...

breast cancer GSK license agreements

Allon Therapeutics selected by the Alzheimer's Disease Cooperative Study

29-Apr-2005 - Allon Therapeutics Inc. announced that its Alzheimer's clinical development program has been selected by the Alzheimer's Disease Cooperative Study (ADCS) in the United States to be included in its submission to receive Phase II clinical trial funding from the U.S. National Institutes of Health ...

Alzheimer's disease clinical trials dosing +3

Theragenics Corporation Agrees to Acquire CP Medical

29-Apr-2005 - Theragenics Corporation(R) announced that it has entered into an agreement to acquire CP Medical, a medical device company. CP Medical is a manufacturer and supplier of innovative sutures, cardiac pacing cables, brachytherapy needles/spacers, and other related medical products sold in the ...

medical devices needles

Acquisition of Eukarion Inc expands Proteome Systems' Biomarker & Drug discovery platform

28-Apr-2005 - Proteome Systems announced the completion of its acquisition of US-based bio-pharmaceutical company, Eukarion Inc. The acquisition provides the company with an extensive patent portfolio of novel, highly innovative anti-oxidant compounds. Several key Eukarion personnel with extensive experience ...

ageing antioxidants biomarker +10

Georgetown University Announces New Grants to Help Build National Cancer Biomedical Informatics Grid

27-Apr-2005 - Researchers at Georgetown University's Lombardi Comprehensive Cancer Center have announced the receipt of more than $800,000 in federal funds to help create the emerging "world wide web of cancer research" - a technological feat that is expected to revolutionize the way that cancer research is ...

informatics oncology

Ceregene Scientific Co-Founder Publishes Alzheimer's Disease Clinical Trial Results in Nature Medicine

27-Apr-2005 - Ceregene, Inc. scientific co- founder, Mark Tuszynski M.D., Ph.D., published in the online edition of Nature Medicine (May 2005) the results of the first ever Phase I clinical study for the treatment of Alzheimer's disease using gene therapy. Ceregene, Inc. has licensed the technology and product ...

absorption Alzheimer's disease BrainCells +9